Activities per year
- 50 - 100 out of 165 results
Search results
-
Facing your Fears
Anthony Venning (Participant), Tasia Oswald (Participant), Paula Redpath (Participant), Sharon Lawn (Participant) & Andrea Morello (Participant)
2018Activity: Other activity types › Other
-
Taking Command of Anxiety
Anthony Venning (Participant), Tasia Oswald (Participant), Paula Redpath (Participant), Sharon Lawn (Participant) & Andrea Morello (Participant)
2018Activity: Other activity types › Other
-
Public Speaker: SAHMRI public and school tours
Charlotte EJ Downes (Participant)
Feb 2018 → May 2022Activity: Other activity types › Other
-
Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. Tricoci P, Neely M, Whitley MJ, Edelstein LC, Simon LM, Shaw C, Fortina P, Moliterno DJ, Armstrong PW, Aylward P, White H, Van de Werf F, Jennings LK, Wallentin L, Held C, Harrington RA, Mahaffey KW, Bray PF. Blood Cells Mol Dis. 2018 Sep;72:37-43. doi: 10.1016/j.bcmd.2018.07.004. Epub 2018 Jul 21. PMID: 30055940. Clinical Trial.
Erin Morton (Other)
2018Activity: Other activity types › Other
-
Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial. Ungar L, Clare RM, Rodriguez F, Kolls BJ, Armstrong PW, Aylward P, Held C, Moliterno DJ, Strony J, Van de Werf F, Wallentin L, White HD, Tricoci P, Harrington RA, Mahaffey KW, Melloni C. J Am Heart Assoc. 2018 Dec 18;7(24):e009609. doi: 10.1161/JAHA.118.009609. PMID: 30526198
Erin Morton (Other)
2018Activity: Other activity types › Other
-
Socioeconomic and ethnic inequities within organised colorectal cancer screening programmes worldwide. Gut, 2018 Apr;67(4):679-687. doi: 10.1136/gutjnl-2016-313311.
C.M. de Klerk (Other), S. Gupta (Other), E. Dekker (Other), M.L. Essink-Bot (Other), Expert Working Group ‘Coalition to reduce inequities in colorectal cancer screening’ of the World Endoscopy Organization (Other) & Graeme P. Young AM FTSE FAHMS AGAF (Other)
2018Activity: Other activity types › Other
-
How Pain affects my Thinking
Anthony Venning (Participant), Tasia Oswald (Participant), Paula Redpath (Participant), Sharon Lawn (Participant) & Andrea Morello (Participant)
2018Activity: Other activity types › Other
-
Pain Medication
Anthony Venning (Participant), Tasia Oswald (Participant), Paula Redpath (Participant), Sharon Lawn (Participant) & Andrea Morello (Participant)
2018Activity: Other activity types › Other
-
Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Davis TME, Mulder H, Lokhnygina Y, Aschner P, Chuang LM, Raffo Grado CA, Standl E, Peterson ED, Holman RR; TECOS Study Group. Diabetes Obes Metab. 2018 Jun;20(6):1427-1434. doi: 10.1111/dom.13242. Epub 2018 Feb 28. PMID: 29405540 Clinical Trial.
Erin Morton (Other)
2018Activity: Other activity types › Other
-
How Anxiety affects Thinking
Anthony Venning (Participant), Tasia Oswald (Participant), Paula Redpath (Participant), Sharon Lawn (Participant) & Andrea Morello (Participant)
2018Activity: Other activity types › Other
-
Student Volunteer: AusBiotech conference 2017
Charlotte EJ Downes (Participant)
Oct 2017Activity: Other activity types › Other
-
Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study. Andrews J, Janssan A, Nguyen T, Pisaniello AD, Scherer DJ, Kastelein JJ, Merkely B, Nissen SE, Ray K, Schwartz GG, Worthley SG, Keyserling C, Dasseux JL, Butters J, Girardi J, Miller R, Nicholls SJ. Cardiovasc Diagn Ther. 2017 Feb;7(1):45-51. doi: 10.21037/cdt.2017.01.01. PMID: 28164012; PMCID: PMC5253449. H-index
Erin Morton (Other)
2017Activity: Other activity types › Other
-
Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. Sharma A, Green JB, Dunning A, Lokhnygina Y, Al-Khatib SM, Lopes RD, Buse JB, Lachin JM, Van de Werf F, Armstrong PW, Kaufman KD, Standl E, Chan JCN, Distiller LA, Scott R, Peterson ED, Holman RR; TECOS Study Group. Diabetes Care. 2017 Dec;40(12):1763-1770. doi: 10.2337/dc17-1091. Epub 2017 Oct 6. PMID: 28986504
Erin Morton (Other)
2017Activity: Other activity types › Other
-
Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. Guimarães PO, Granger CB, Stebbins A, Chiswell K, Held C, Hochman JS, Krug-Gourley S, Lonn E, Lopes RD, Stewart RAH, Vinereanu D, Wallentin L, White HD, Hagström E, Danchin N. J Am Heart Assoc. 2017 Sep 14;6(9):e006695. doi: 10.1161/JAHA.117.006695. PMID: 28912210. Clinical Trial.
Erin Morton (Other)
2017Activity: Other activity types › Other
-
NHMRC Grant Management Solution Working Group
Roger Yazbek (Participant)
29 Nov 2017 → 17 May 2021Activity: Other activity types › Other
-
Fundraising Volunteer: Cancer Council Relay for Life
Charlotte EJ Downes (Participant)
Oct 2017Activity: Other activity types › Other
-
Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. Stewart RAH, Held C, Hadziosmanovic N, Armstrong PW, Cannon CP, Granger CB, Hagström E, Hochman JS, Koenig W, Lonn E, Nicolau JC, Steg PG, Vedin O, Wallentin L, White HD; STABILITY Investigators. J Am Coll Cardiol. 2017 Oct 3;70(14):1689-1700. doi: 10.1016/j.jacc.2017.08.017. PMID: 28958324 Clinical Trial.
Erin Morton (Other)
2017Activity: Other activity types › Other
-
Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial. Josse RG, Majumdar SR, Zheng Y, Adler A, Bethel MA, Buse JB, Green JB, Kaufman KD, Rodbard HW, Tankova T, Westerhout CM, Peterson ED, Holman RR, Armstrong PW; TECOS Study Group. Diabetes Obes Metab. 2017 Jan;19(1):78-86. doi: 10.1111/dom.12786. Epub 2016 Oct 6. PMID: 27607571 Clinical Trial.
Erin Morton (Other)
2017Activity: Other activity types › Other
-
Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS. Engel SS, Suryawanshi S, Stevens SR, Josse RG, Cornel JH, Jakuboniene N, Riefflin A, Tankova T, Wainstein J, Peterson ED, Holman RR; TECOS Study Group. Diabetes Obes Metab. 2017 Nov;19(11):1587-1593. doi: 10.1111/dom.12983. Epub 2017 Jul 7. PMID: 28432745 Clinical Trial.
Erin Morton (Other)
2017Activity: Other activity types › Other
-
Post Traumatic Stress Disorder: Processing the Past, Redefining the Future
Anthony Venning (Participant), Paula Redpath (Participant) & Tassia K. Oswald (Participant)
30 Jan 2017Activity: Other activity types › Other
-
Anxiety group program
Anthony Venning (Participant), Paula Redpath (Participant), Tasia Oswald (Participant), Andrea Morello (Participant) & Sharon Lawn (Participant)
2017Activity: Other activity types › Other
-
Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease. Gryka RJ, Buckley LF, Anderson SM. Drugs R D. 2017 Mar;17(1):65-72. doi: 10.1007/s40268-016-0158-4. PMID: 28063023. Review.
Erin Morton (Other)
2017Activity: Other activity types › Other
-
Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. Held C, White HD, Stewart RAH, Budaj A, Cannon CP, Hochman JS, Koenig W, Siegbahn A, Steg PG, Soffer J, Weaver WD, Östlund O, Wallentin L; STABILITY Investigators. J Am Heart Assoc. 2017 Oct 24;6(10):e005077. doi: 10.1161/JAHA.116.005077. PMID: 29066452. Clinical Trial.
Erin Morton (Other)
2017Activity: Other activity types › Other
-
Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib. Yeo A, Li L, Warren L, Aponte J, Fraser D, King K, Johansson K, Barnes A, MacPhee C, Davies R, Chissoe S, Tarka E, O'Donoghue ML, White HD, Wallentin L, Waterworth D. PLoS One. 2017 Jul 28;12(7):e0182115. doi: 10.1371/journal.pone.0182115. eCollection 2017. PMID: 28753643.
Erin Morton (Other)
2017Activity: Other activity types › Other
-
Re-Thinking Chronic Pain
Paula Redpath (Participant), Anthony Venning (Participant), Tasia Oswald (Participant) & Cindy Wall (Participant)
30 Jan 2017Activity: Other activity types › Other
-
Pain Group program
Paula Redpath (Participant), Anthony Venning (Participant), Tasia Oswald (Participant), Andrea Morello (Participant) & Sharon Lawn (Participant)
2017Activity: Other activity types › Other
-
Perinatal Mental health: Bouncing Back after Baby
Paula Redpath (Participant), Anthony Venning (Participant), Fiona Glover (Participant) & Tassia K. Oswald (Participant)
30 Jan 2017Activity: Other activity types › Other
-
Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial. Harskamp RE, Clare RM, Ambrosio G, Held C, Lokhnygina Y, Moliterno DJ, White HD, Aylward PE, Armstrong PW, Mahaffey KW, Harrington RA, Van de Werf F, Wallentin L, Strony J, Tricoci P. Eur Heart J Acute Cardiovasc Care. 2017 Mar;6(2):155-163. doi: 10.1177/2048872616633880. Epub 2016 Sep 20. PMID: 26895973 Clinical Trial.
Erin Morton (Other)
2016Activity: Other activity types › Other
-
Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. Armaganijan LV, Alexander KP, Huang Z, Tricoci P, Held C, Van de Werf F, Armstrong PW, Aylward PE, White HD, Moliterno DJ, Wallentin L, Chen E, Harrington RA, Strony J, Mahaffey KW, Lopes RD. Am Heart J. 2016 Aug;178:176-84. doi: 10.1016/j.ahj.2016.05.012. Epub 2016 Jun 9. PMID: 27502866
Erin Morton (Other)
2016Activity: Other activity types › Other
-
Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar. Déry JP, Mahaffey KW, Tricoci P, White HD, Podder M, Westerhout CM, Moliterno DJ, Harrington RA, Chen E, Strony J, Van de Werf F, Ziada KM, Held C, Aylward PE, Armstrong PW, Rao SV. Catheter Cardiovasc Interv. 2016 Aug;88(2):163-73. doi: 10.1002/ccd.26335. Epub 2015 Dec 23. PMID: 26698636 Clinical Trial.
Erin Morton (Other)
2016Activity: Other activity types › Other
-
Pancreatic Safety of Sitagliptin in the TECOS Study. Buse JB, Bethel MA, Green JB, Stevens SR, Lokhnygina Y, Aschner P, Grado CR, Tankova T, Wainstein J, Josse R, Lachin JM, Engel SS, Patel K, Peterson ED, Holman RR; TECOS Study Group. Diabetes Care. 2017 Feb;40(2):164-170. doi: 10.2337/dc15-2780. Epub 2016 Sep 14. PMID: 27630212. Clinical Trial.
Erin Morton (Other)
2016Activity: Other activity types › Other
-
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group. N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. PMID: 26052984 Clinical Trial.
Erin Morton (Other)
2015Activity: Other activity types › Other
-
STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases. Hassan M. Glob Cardiol Sci Pract. 2015 Jan 26;2015:6. doi: 10.5339/gcsp.2015.6. eCollection 2015. PMID: 25830150.
Erin Morton (Other)
2015Activity: Other activity types › Other
-
Story board and E-Collage for the Dignity in Mental Health Project, World Federation for Mental Health (WFMH).
Sharon Lawn (Participant)
2015Activity: Other activity types › Other
-
Development of an online screening tool to identify the needs of new clients and refer them to service
Sharon Lawn (Participant), Andrea Morello (Participant), Candice Oster (Participant), Paula Redpath (Participant), Anthony Venning (Participant), Paul Cromarty (Participant) & Aaron Drummond (Participant)
2015Activity: Other activity types › Other
-
Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). Cornel JH, Tricoci P, Lokhnygina Y, Moliterno DJ, Wallentin L, Armstrong PW, Aylward PE, Clare RM, Chen E, Leonardi S, Van de Werf F, White HD, Held C, Strony J, Mahaffey KW, Harrington RA. Am J Cardiol. 2015 May 15;115(10):1325-32. doi: 10.1016/j.amjcard.2015.02.043. Epub 2015 Feb 18. PMID: 25776457 Clinical Trial.
Erin Morton (Other)
2015Activity: Other activity types › Other
-
Redesigning TRACER trial after TRITON. Serebruany VL. Int J Cardiol. 2015 Oct 15;197:44-7. doi: 10.1016/j.ijcard.2015.06.020. Epub 2015 Jun 18. PMID: 26126053
Erin Morton (Other)
2015Activity: Other activity types › Other
-
Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery. van Diepen S, Tricoci P, Podder M, Westerhout CM, Aylward PE, Held C, Van de Werf F, Strony J, Wallentin L, Moliterno DJ, White HD, Mahaffey KW, Harrington RA, Armstrong PW. J Am Heart Assoc. 2015 Dec 15;4(12):e002546. doi: 10.1161/JAHA.115.002546. PMID: 26672080 Clinical Trial.
Erin Morton (Other)
2015Activity: Other activity types › Other
-
Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis. Diehl P, Bode C, Duerschmied D. Ther Clin Risk Manag. 2015 Aug 3;11:1133-8. doi: 10.2147/TCRM.S55469. eCollection 2015. PMID: 26346960. Review.
Erin Morton (Other)
2015Activity: Other activity types › Other
-
The FDA review on data quality and conduct in vorapaxar trials: Much better than in PLATO, but still not perfect. Serebruany VL, Choi SY, Kim MH. Int J Cardiol. 2016 Feb 15;205:13-16. doi: 10.1016/j.ijcard.2015.12.001. Epub 2015 Dec 3. PMID: 26709134
Erin Morton (Other)
2015Activity: Other activity types › Other
-
Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). Whellan DJ, Tricoci P, Chen E, Huang Z, Leibowitz D, Vranckx P, Marhefka GD, Held C, Nicolau JC, Storey RF, Ruzyllo W, Huber K, Sinnaeve P, Weiss AT, Dery JP, Moliterno DJ, Van de Werf F, Aylward PE, White HD, Armstrong PW, Wallentin L, Strony J, Harrington RA, Mahaffey KW. J Am Coll Cardiol. 2014 Mar 25;63(11):1048-57. doi: 10.1016/j.jacc.2013.10.048. Epub 2013 Nov 21. PMID: 24211500 Clinical Trial.
Erin Morton (Other)
2014Activity: Other activity types › Other
-
PAR-1 antagonist vorapaxar favorably improves global thrombotic status in patients with coronary disease. Rosser G, Tricoci P, Morrow D, Christopoulos C, Niespialowska-Steuden MN, Kozarski R, Wilcox R, Gorog DA. J Thromb Thrombolysis. 2014 Nov;38(4):423-9. doi: 10.1007/s11239-014-1075-4. PMID: 24676931 Clinical Trial.
Erin Morton (Other)
2014Activity: Other activity types › Other
-
Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER. White HD, Huang Z, Tricoci P, Van de Werf F, Wallentin L, Lokhnygina Y, Moliterno DJ, Aylward PE, Mahaffey KW, Armstrong PW. J Am Heart Assoc. 2014 Jul 10;3(4):e001032. doi: 10.1161/JAHA.114.001032. PMID: 25012288. Clinical Trial.
Erin Morton (Other)
2014Activity: Other activity types › Other
-
To hydrolyze or not to hydrolyze: the dilemma of platelet-activating factor acetylhydrolase. Marathe GK, Pandit C, Lakshmikanth CL, Chaithra VH, Jacob SP, D'Souza CJ. J Lipid Res. 2014 Sep;55(9):1847-54. doi: 10.1194/jlr.R045492. Epub 2014 May 23. PMID: 24859738. Review.
Erin Morton (Other)
2014Activity: Other activity types › Other